ATE89314T1 - Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. - Google Patents

Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.

Info

Publication number
ATE89314T1
ATE89314T1 AT86901613T AT86901613T ATE89314T1 AT E89314 T1 ATE89314 T1 AT E89314T1 AT 86901613 T AT86901613 T AT 86901613T AT 86901613 T AT86901613 T AT 86901613T AT E89314 T1 ATE89314 T1 AT E89314T1
Authority
AT
Austria
Prior art keywords
promotor
produced
human metallothionein
expression systems
mammalian expression
Prior art date
Application number
AT86901613T
Other languages
English (en)
Inventor
Peter J Kushner
Claire L Cofer
Jeffrey S Friedman
Karen D Talmadge
Original Assignee
Scios Nova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Nova Inc filed Critical Scios Nova Inc
Application granted granted Critical
Publication of ATE89314T1 publication Critical patent/ATE89314T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6486—Renin (3.4.23.15)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23015—Renin (3.4.23.15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT86901613T 1985-02-13 1986-02-11 Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. ATE89314T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70129685A 1985-02-13 1985-02-13
US80167485A 1985-11-25 1985-11-25
PCT/US1986/000296 WO1986004920A1 (en) 1985-02-13 1986-02-11 Human metallothionein-ii promoter in mammalian expression system
EP86901613A EP0217822B1 (de) 1985-02-13 1986-02-11 Menschlicher metallothionein ii-promotor in säugetierexpressionssystemen

Publications (1)

Publication Number Publication Date
ATE89314T1 true ATE89314T1 (de) 1993-05-15

Family

ID=27106764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86901613T ATE89314T1 (de) 1985-02-13 1986-02-11 Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.

Country Status (9)

Country Link
US (1) US5089397A (de)
EP (1) EP0217822B1 (de)
AT (1) ATE89314T1 (de)
AU (1) AU580145B2 (de)
CA (1) CA1338829C (de)
DE (1) DE3688418T2 (de)
DK (1) DK488386A (de)
ES (1) ES8707564A1 (de)
WO (1) WO1986004920A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659805A (en) * 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
IL78314A0 (en) * 1985-04-03 1986-07-31 Biotechnology Res Ass Expression vectors and methods for the production of recombinant human renin
WO1987002037A1 (en) * 1985-09-26 1987-04-09 Genetics Institute, Inc. Pulmonary surfactant proteins
AU6522486A (en) * 1985-10-04 1987-04-24 Biotechnology Research Partners Limited Recombinant apolipoproteins and methods
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
AU613876B2 (en) * 1986-10-01 1991-08-15 Merck & Co., Inc. Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
GB8629153D0 (en) * 1986-12-05 1987-01-14 Ciba Geigy Ag Hybrid proteins
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5830685A (en) * 1990-02-09 1998-11-03 Genentech, Inc. Method of producing proteins using mammalian lung cell lines
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
JP2524939B2 (ja) * 1991-12-03 1996-08-14 株式会社ニチレイ エンハンサ−及びその用途
US5342782A (en) * 1992-02-24 1994-08-30 Washington University Tightly regulated expression system for eucaryotic cells
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
US5962664A (en) * 1993-05-13 1999-10-05 Friedhoff; Arnold J. Psychosis protecting nucleic acid, peptides, compositions and method of use
JPH07163368A (ja) * 1993-12-15 1995-06-27 Hayashibara Biochem Lab Inc 組換えｄｎａとその組換えｄｎａを含む形質転換体
GB9506051D0 (en) * 1995-03-24 1995-05-10 Univ Singapore Gene expression
AUPN442295A0 (en) * 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells
US6297027B1 (en) 1996-07-31 2001-10-02 Purina Mills, Inc. Bovine leptin protein, nucleic acid sequences coding therefor and uses thereof
US6277592B1 (en) 1996-07-31 2001-08-21 Purina Mills, Inc. Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
JP2000517188A (ja) 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6696411B1 (en) * 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
JP2002512039A (ja) 1998-04-22 2002-04-23 コーネル リサーチ ファンデーション インク． イヌエリスロポエチン遺伝子および組換えタンパク質
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
WO2002068668A2 (en) * 2001-02-22 2002-09-06 Immunex Corporation Compositions and methods for production cell culture
WO2002095061A1 (en) * 2001-05-18 2002-11-28 New York University Methods of screening test substances for treating or preventing diseases involving an oxidative stress
NZ538094A (en) 2002-07-09 2007-01-26 Baxter Int Serum free and animal protein free culture medium for cultivation of cells
CA2618939A1 (en) * 2004-08-13 2006-04-27 Jaguar Bioscience Inc. Systems and methods for identifying diagnostic indicators
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
DE602005026548D1 (de) * 2004-11-02 2011-04-07 Ares Trading Sa Serumfreies kulturmedium für säugerzellen
DK1907561T3 (da) * 2005-06-24 2013-12-02 Enteris Biopharma Inc Cellelinjer til ekspression af enzym, der er anvendeligt i fremstillingen af amiderede produkter
KR101422435B1 (ko) 2006-01-04 2014-07-22 박스터 헬쓰케어 에스에이 올리고펩티드-무함유 세포 배양 배지
PL2592148T3 (pl) 2007-10-12 2019-01-31 F. Hoffmann-La Roche Ag Ekspresja białka z wielu kwasów nukleinowych
ES2337973B8 (es) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
ES2330826B1 (es) 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. Sistema para empaquetamiento de adenovirus de alta capacidad.
CA3033577A1 (en) 2008-11-10 2010-05-14 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
WO2010088537A2 (en) 2009-01-29 2010-08-05 Alnylam Pharmaceuticals, Inc. Improved lipid formulation
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
WO2010129709A1 (en) 2009-05-05 2010-11-11 Alnylam Pharmaceuticals, Inc. Lipid compositions
SMT201800499T1 (it) 2009-06-10 2018-11-09 Arbutus Biopharma Corp Formulazione lipidica migliorata
US9029338B2 (en) 2009-08-14 2015-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
IL300109A (en) 2010-06-03 2023-03-01 Alnylam Pharmaceuticals Inc Biodegradable lipids for the transfer of active substances
EP2407534A1 (de) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Verfahren und Reagenzien zum Erhalt von transkriptionell aktiven virusähnlichen Artikeln und rekombinante Virionen
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
EP2663548B1 (de) 2011-01-11 2017-04-05 Alnylam Pharmaceuticals, Inc. Pegylierte lipide und ihre verwendung zur wirkstofffreisetzung
US9701623B2 (en) 2011-09-27 2017-07-11 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
EP2650682A1 (de) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Asymmetrische Ester von als Schmiermittel geeigneten Fettsäuren
EP2859120B1 (de) 2012-06-06 2018-11-14 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Verfahren zur diagnose und prognose von lungenkrebsmetastasen
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
EP2687852A1 (de) 2012-07-17 2014-01-22 Laboratorios Del. Dr. Esteve, S.A. Verfahren zur Diagnose und Behandlung des chronischen Erschöpfungssyndroms
ES2744244T3 (es) 2012-10-12 2020-02-24 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF
CA2906394A1 (en) 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
KR20150122786A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
CN105980576B (zh) 2013-10-09 2021-07-16 生物医学研究机构基金会 用于源自乳腺癌的骨转移癌的预后和治疗的方法
EP3089755A1 (de) 2014-01-03 2016-11-09 Fundacion Biofisica Bizkaia Vlps, verfahren zu deren gewinnung und anwendungen davon
KR101867134B1 (ko) * 2015-03-23 2018-06-12 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
RU2750721C2 (ru) 2017-03-10 2021-07-01 Ф. Хоффманн-Ля Рош Аг Способ получения мультиспецифических антител
PT115073A (pt) 2018-10-09 2020-05-29 Inst De Biologia Molecular E Celular Ibmc Ácido nucleico para ativar a expressão e a produção de proteínas
EP4371569A1 (de) 2022-11-16 2024-05-22 Universidad del País Vasco/Euskal Herriko Unibertsitatea Vlps gegen akute myeloische leukämie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ATE72583T1 (de) * 1981-11-23 1992-02-15 University Patents Inc Steuerung der dna-sequenzen-transkription.
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
US4601978A (en) * 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
CA1224168A (en) * 1982-12-23 1987-07-14 Dean H. Hamer Human growth hormone produced by recombinant dna in mouse cells
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin

Also Published As

Publication number Publication date
EP0217822B1 (de) 1993-05-12
US5089397A (en) 1992-02-18
ES8707564A1 (es) 1987-08-01
AU5513586A (en) 1986-09-10
WO1986004920A1 (en) 1986-08-28
DK488386A (da) 1986-12-15
DK488386D0 (da) 1986-10-13
EP0217822A4 (de) 1989-05-11
ES551913A0 (es) 1987-08-01
DE3688418D1 (de) 1993-06-17
DE3688418T2 (de) 1993-08-26
EP0217822A1 (de) 1987-04-15
CA1338829C (en) 1997-01-07
AU580145B2 (en) 1989-01-05

Similar Documents

Publication Publication Date Title
ATE89314T1 (de) Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
ES2080809T3 (es) Receptores de factor de necrosis tumoral alfa y beta.
IL94128A (en) Nucleic acids encoding vascular endothelial cell growth factors, expression vectors and host cells comprising such nucleic acids and methods of producing such vascular endothelial growth factors
DE3479321D1 (en) Biosynthetically produced human nerve growth factor, process for producing it, compositions containing it, dna sequence encoding it, vectors containing the sequence and host cells transformed thereby
KR880014110A (ko) 인체 프로아포지방단백질 a-i의 발현
AU2200388A (en) Process for producing recombinant human factor viii:c and transformant to be used therefor
ATE88501T1 (de) Rekombinante dns-expressionsvektoren.
GR3021198T3 (en) Interleukin-4 protein having bcgf and tcgf activity on human cells (human interleukin-4)
ES8606489A1 (es) Un metodo de producir una proteina de interleuquina-2-humana no glicosilada sustancialmente pura
ATE125869T1 (de) Wachstumshormonfusionsproteine.
ATE26463T1 (de) Verfahren zur herstellung von menschlichem leukozyten-interferon.
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
DE122004000009I1 (de) Methode zur Herstellung von menschlichen Wachstumshormonen.
CA1267497C (en) PROTEIN RECOVERY
Fukunaga et al. Constitutive production of human interferons by mouse cells with bovine papillomavirus as a vector.
DE3688900D1 (de) Expression von protein c.
EP0111389A3 (de) Wesentlich sauberes Schweinewachstumshormon, DNS-Sequenzen dafür und Expressionsvektoren und transfektierte Mikroorganismen zur Herstellung von Schweinewachstumshormon
AU6833387A (en) Expression of eucaryotic proteins
DE3852777D1 (de) Verfahren zur Konstruktion einer animalen Zellinie für die Herstellung von humanem Interferon-beta.
AU5520390A (en) Dna coding for protein capable of combining with enhancer of alpha-fetoprotein gene
ES8506194A1 (es) Polipeptido de interferon- humano
DE3650477D1 (de) Produktion von Cystinreste enthaltenden aktiven Proteinen
IL82207A0 (en) Production of peptides,recombinant plasmid used therefor and animal cells transformed therewith
CA1312566C (en) Method for increasing the expression of polypeptides in recombinant cell culture
ATE91717T1 (de) Verfahren zur herstellung von proteinen in loeslicher form.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time